Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin in acute pancreatitis
ISRCTN89716803Phase 4Completed
- Sponsor
- Dayanand Medical College & Hospital
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in acute pancreatitis (AP) comparing Rifaximin + standard treatment with Placebo + standard treatment (2 arms). Primary endpoint: Composite infectious complications at day 30. Started May 2024; status: completed.
02
Drugs
rifaximin
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on ISRCTN89716803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN89716803.